Market Place
Sourcing Support
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna
11 Oct 2022 //
GLOBENEWSWIRE
Brooklyn`s immunotherapy flops phase 2 in oral cavity cancer
28 Jul 2022 //
FIERCEBIOTECH
Brooklyn ImmunoTherapeutics Announces Results of PII Study of IRX-2
26 Jul 2022 //
GLOBENEWSWIRE
Brooklyn Immuno Announces Receipt of Nasdaq Notification
17 Jun 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Board Changes
07 Jun 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management
31 May 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq
27 May 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Establishment of New Research
21 Apr 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Q4 and Full Year 2021 Financial Results
18 Apr 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTx says Closing of $12 M Private Placement
09 Mar 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTx says $12 M Private Placement
07 Mar 2022 //
GLOBENEWSWIRE
Brooklyn Immuno Provides Update on Regenerative Medicine IP Portfolio
13 Jan 2022 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
17 Dec 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
14 Dec 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
02 Dec 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement
19 Nov 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
14 Oct 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics snags Roivant CMO for same post
24 Sep 2021 //
FIERCEBIOTECH
Brooklyn ImmunoTherapeutics Reports Inducement Grants
23 Sep 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
22 Sep 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics lays out timeline of future planned studies
20 Sep 2021 //
SEEKINGALPHA
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call
13 Sep 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Adjourns Annual Meeting of Stockholders
20 Aug 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call
16 Aug 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference
13 Aug 2021 //
GLOBENEWS WIRE
Brooklyn Immuno Reports Inducement Grants
23 Jul 2021 //
GLOBENEWSWIRE
Brooklyn Immuno Reports Inducement Grants
23 Jul 2021 //
GLOBENEWSWIRE
Brooklyn Immuno Reports Inducement Grants
23 Jul 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
13 Jul 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics to Present at Access to Giving Investor Conference
12 Jul 2021 //
GLOBENEWSWIRE
Brooklyn ImmunoTherapeutics Reports Inducement Grants
06 Jul 2021 //
GLOBENEWSWIRE
Brooklyn Executes Letter of Intent to Acquire Novellus Therapeutics
15 Jun 2021 //
BIOSPACE
Brooklyn ImmunoTherapeutics to Acquire Novellus Therapeutics
14 Jun 2021 //
BIOSPACE
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap
26 May 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA
24 May 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA
24 May 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Announces Publication Results of IRX-2 Monotherapy
11 May 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2
11 May 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License
16 Apr 2021 //
BIOSPACE
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License mRNA
16 Apr 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Pays $1 M Towards Acquisition of License for Mrna
15 Apr 2021 //
BIOSPACE
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
25 Mar 2021 //
BUSINESSWIRE
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
25 Mar 2021 //
BIOSPACE
CORRECTING & REPLACING Brooklyn ImmunoTherapeutics Announces Initiation of Ph 2
09 Feb 2021 //
BUSINESSWIRE
